One of the key strengths of this study lies in its innovative focus on the prognostic value of whole-body Total Molecular Volume (wb TMV) derived from PSMA PET/CT in the setting of biochemical recurrence (BCR) of prostate cancer. The gene discussed is FOLH1; the disease is prostate carcinoma.